Skip to main content
. 2015 Jan 7;9(4):850–860. doi: 10.1016/j.molonc.2014.12.011

Figure 3.

Figure 3

Detection of KRAS mutations in CTCs of CRC patients. Illustration of a patient with wild‐type KRAS using (A) HRM and (B) Sanger. KRAS mutation was detected in patient FIT‐001's tumor and CTCs by (C) HRM and (D) Sanger. (E) ASPCR identified the mutations in FIT‐001 and FIT‐029 as KRAS G12D, as verified by (F) Sanger. (G) KRAS mutation detected by HRM in a (H) Sanger sequencing‐negative patient FIT‐003. (I) ASPCR identified the mutation in FIT‐003 as KRAS G13D mutation.